Immuron Limited (IMRN)

11.1 -0.65 (-5.532%)

IEX Real-Time Price

March 20, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 11.75

Price Open 11.4

Volume: 5,838

Avg Volume: 19,065

Market Cap: 36.2M

P/E Ratio -

52 Wk Range 4.47-16.7

IMRN Short Interest Statistics

Report Date
Float Share
Short Interest
Short Ratio
Short % to Float






Your Daily Pharma Scoop: Sunesis Update, Cesca Signs Agreement, Inovio's Preliminary Results (2018-03-15 08:00 SeekingAlpha)

Analysis of top Seeking Alpha coverage: Sunesis Pharmaceuticals Today we will discuss Sunesis Pharmaceuticals ( SNSS ), which plunged last week after the company provided an update on the phase 1b/2 study evaluating its Vecabrutinib (SNS-062) in adult patients with chronic lymphocytic l…


Immunron secures A$5.1M capital raise; shares down 4% premarket (2018-03-14 07:57 SeekingAlpha)

Thinly traded nano cap Immunorn Limited (NASDAQ: IMRN )is down 4% premarket on light volume on the heels of its announcement that it has raised A$5.1M via the private placement of stock and options with a U.S. institutional investor. More news on: Immuron Limited, Healt…


Immuron's IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81% (2018-03-08 12:23 SeekingAlpha)

Thinly traded nano cap Immuron Limited ( IMRN +81.4% ) is up on a 13x surge in volume, albeit on turnover of only 148K shares, on the heels of its announcement of positive results from a Phase 2 proof-of-concept clinical trial assessing IMM-124E in 133 NASH patients, a reversal of fort…


Premarket analyst action - healthcare (2017-10-18 08:56 SeekingAlpha)

Krystal Biotech (Pending: KRYS ) initiated with Buy rating and $23 (137% upside) price target by Ladenburg Thalmann. More news on: Krystal Biotech, Immuron Limited, T2 Biosystems, Healthcare stocks news, Read more …


Stop Holidays from Becoming Horror Days (2016-11-23 06:00 PR Newswire)

NEW YORK , Nov. 23,2016 /PRNewswire/ --It is not only overseas holidays that can be ruined by the dreaded T raveller's D iarrhoea. While most commonly associated with street food and travel to countries with poor hygiene, Traveller's Diarrhoea is also a common complaint f…


Therapy Focus - NASH Projects Set For Data In Dog Days Of Summer (2016-05-03 13:33 SeekingAlpha)

Three of the industry's nine projects that are in randomised, controlled trials for non-alcoholic steatohepatitis are due to see readouts in the late summer or early autumn this year, potentially making for an eventful period in this still nascent but closely followed therapy area (see table b…



Shares Outstanding: 3.26M

Top 15 Institution Percent: 0.40

Price To Sales: 29.83

Price To Book: 9.42

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -85.85

Return On Equity: -106.07

Profit Margin: N/A

Price History

Beta: 4.86

50-day Moving Avg: 8.50

200-day Moving Avg: 6.59

YTD Change: 109.43

5-day Change: -12.60

1-month Change: 42.67

3-month Change: 120.24

6-month Change: 78.17

1-year Change: 32.85

Revenue Per Share: 0.00

Revenue Per Employee: 0.00


Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -

Company Profile

Name: Immuron Limited

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare


Immuron Ltd is a biopharmaceutical company which develops polyclonal antibodies for the treatment and prevention of diseases. It products include Travelan, IMM-124E for NASH and IMM-529 for Clostridium difficile infection.